RayKnowChina Research Map
Shortlist0

Taiyuan

Shanxi Cancer Hospital

山西省肿瘤医院

Listed for 7 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanxi Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  2. Stomach cancer胃癌8 papers led
  3. Osteosarcoma骨肉瘤2 papers led
  4. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  5. Ewing sarcoma尤文肉瘤1 paper led
  6. Multiple myeloma多发性骨髓瘤0 papers led
  7. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 1120242025: 002025

3 hospitals in Taiyuan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  2. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyMolecular markers & genomics
Departments in papersRadiation oncologyGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led4
  1. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.2024Thoracic cancerFree full text
  2. Submucosal oesophageal squamous cell carcinoma with lymph node metastasis: a case report and literature review.2022BMC gastroenterologyFree full text
  3. MicroRNA-137 Inhibits Esophageal Squamous Cell Carcinoma by Downregulating DAAM1.2022Protein and peptide letters
  4. The Role of DBR1 as a Candidate Prognosis Biomarker in Esophageal Squamous Cell Carcinoma.2022Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)1
  1. [Fat1 inhibits cell proliferation via ERK signaling pathway in esophageal squamous cell carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status8
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  4. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  5. SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingNCT05022654Study sitePhase 2Start 2021-12
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  7. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652Study siteStart 2018-10
  8. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownNCT02319187Study sitePhase 3Start 2014-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 8 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.08%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 1120242025: 112025

1 hospital in Taiyuan for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07689851

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  3. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  4. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  5. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  6. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  7. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  8. Recruiting
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05687357

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan

  9. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopySurgeryChemotherapy & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiation oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led8
  1. Prognostic value of c-MET protein expression in gastric cancer patients: a systematic review and meta-analysis.2025Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  2. LncRNA LINC01278 Regulates the Prognosis and Related Mechanisms of Gastric Cancer by Targeting miR-129-5p.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  3. CircRNA circSLIT2 is a novel diagnostic and prognostic biomarker for gastric cancer.2023Wiener klinische Wochenschrift
  4. Clinicopathological Significance and Molecular Mechanism of AKT/GSK3β Pathway-based Fibrillin-1 Expression in Gastric Cancer Progression.2022Cellular and molecular biology (Noisy-le-Grand, France)
  5. Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: Based on a retrospective and observational study of follow-up within 3 years of 843 patients.2022MedicineFree full text
  6. Ubiquitin-specific protease 1 overexpression indicates poor prognosis and promotes proliferation, migration, and invasion of gastric cancer cells.2022Tissue & cell
  7. Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.2021BMC cancerFree full text
  8. Hypoxia-Induced LXRα Contributes to the Migration and Invasion of Gastric Cancer Cells.2021Folia biologica
Chinese-language papers (not in the count)2
  1. [Effect of acupuncture on functional delayed gastric emptying after gastric cancer surgery based on enhance recovery after surgery].2023Zhongguo zhen jiu = Chinese acupuncture & moxibustionRCT
  2. [Analysis of the clinical confusion and controversy of esophagogastric junction tumor from basic anatomy].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status21
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingNCT07689851Study sitePhase 2Start 2026-07
  3. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  4. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  5. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  6. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  7. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  8. Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Study sitePhase 2Start 2023-03
  9. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  10. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTerminatedNCT06585488Study sitePhase 1Start 2024-12
  11. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Study sitePhase 2Start 2023-04
  12. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  13. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  14. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  15. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  16. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  17. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  18. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  19. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  20. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  21. Esophageal Cancer Genetics StudiesCompletedNCT00341276Study siteStart 1995-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

5 hospitals in Taiyuan for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

2 hospitals in Taiyuan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Rectal adenocarcinoma coexisting with metastatic small intestinal stromal tumor: case report and literature review].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Study siteN/AStart 2016-05

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Taiyuan for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

4 hospitals in Taiyuan for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taiyuan for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaStatus unknownNCT04714593Lead sponsorPhase 1/Phase 2Start 2021-01

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山西省肿瘤医院

Shanxi Cancer Hospital

太原

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data